Carotid Artery Stenting With Cilostazol Addition for Restenosis
Carotid Artery Stenting With Cilostazol Addition for Restenosis
CAS-CARE study was conducted to evaluate the inhibitory effect of cilostazol, compared to
 that of other antiplatelet drugs, on in-stent restenosis following carotid artery stenting
 (CAS) in patients scheduled to undergo CAS. Study design is Multicenter Prospective
 Ranodomized Controlled Study, rondomized by cilostazol/non-cilostazol group prior to CAS. 900
 patients will be enrolled for 2 years and followed 2 years with in-stent restenosis after
 CAS, evaluated by carotid ultrasound and angiography.
Restenosis after carotid artery stenting (CAS) is a critical issue. Cilostazol can reduce
 restenosis after interventions in coronary or femoropopliteal arteries. The investigators
 confirmed and published periprocedural cilostazol administration reduced incidences of
 in-stent restenosis (ISR) or target vessel revascularization (TVR) after CAS,
 retrospectively.

 CAS-CARE study is Multicenter Prospective Ranodomized Controlled Study. Patients, scheduled
 for CAS within 30 days, 50% or more symptomatic carotid stenosis or 80% or more asymptomatic
 carotid stenosis, will enroll and randomize by cilostazol/non-cilostazol group. 900 patients
 will be enrolled for 2 years and followed 2 years with in-stent restenosis after CAS,
 evaluated by carotid ultrasound and angiography. And, evaluate cardiovascular events,
 including stroke, myocardial infarction, and hemorrhagic events in periprocedural period and
 followed period. In this study, ISR is diagnosed by ultrasound and DSA/CTA. Equivalence of
 CTA to ultrasound will be studied.
Inclusion Criteria:

 -  50% or more symptomatic carotid artery stenosis or 80% or more asymptomatic carotid
 artery stenosis

 -  scheduled for carotid artery stenting within 30 days

 -  45 or more years-old and less than 80 years old

 -  antiplatelet agents can be administratered orally

 -  follow-up is anticipated possible for 2 years after CAS

 -  self-supporoted in daily activities (modified Rankin Scale 2 or less)

 -  patients who have given informed consent to participation in the study

 Exclusion Criteria:

 -  received endovascular interevention

 -  scheduled for bilateral carotid intervention

 -  aortitis or cvasculitis

 -  congessive heart failure

 -  ischemic stroke within 48 hours

 -  hemorrhagic stroke within 90 days

 -  renal failure